Solid discussion. The danuglipron story is a good reminder that drug development is hard and that being first with a concept (oral non-peptide GLP-1) doesn't guarantee being first to market. Execution, molecular properties, and clinical outcomes matter more than the idea itself.

For the community: while danuglipron is struggling, the broader oral GLP-1 pipeline is alive and well. Orforglipron, oral sema 50mg, amycretin oral, and multiple earlier-stage programs are all advancing. The future of obesity treatment will almost certainly include effective oral options, even if danuglipron specifically doesn't make it.